What is the 13F Pro Quality Score for KOD?

13F Pro ranks Kodiak Sciences Inc. (KOD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KOD's current score at https://13fpro.ai/research/KOD (free sign-up required for the full ranking).

Which hedge funds own the most KOD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KOD include BAKER BROS. ADVISORS, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/KOD as soon as new 13F filings post.

Where does 13F Pro source KOD data?

All Kodiak Sciences Inc. fundamentals and ownership data come directly from SEC EDGAR. Kodiak Sciences Inc. files with the SEC under CIK 1468748. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KOD in?

Kodiak Sciences Inc. (KOD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KOD research updated on 13F Pro?

KOD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Kodiak Sciences Inc.(KOD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1468748 KOD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

KOD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Kodiak Sciences Inc. (KOD), a Healthcare sector company. KOD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Kodiak Sciences Inc. reports net income of $-58.2M, free cash flow of $-41.0M. Top institutional holders of KOD by reported 13-F value include BAKER BROS. ADVISORS, BlackRock,, STATE STREET, based on the most recent SEC filings. KOD trades on the Nasdaq exchange and files with the SEC under CIK 1468748. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KOD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kodiak Sciences Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-58.2M

Free Cash Flow

Q1 2026

$-41.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-30.5% YoY

$-230.0MFY 2025

FY21 $-267.0MFY23 $-260.5MFY24 $-176.2MFY25 $-230.0M

Operating Income

-25.4% YoY

$-234.4MFY 2025

FY21 $-267.1MFY23 $-277.3MFY24 $-186.8MFY25 $-234.4M

EPS (Diluted)

-29.0% YoY

$-4.32FY 2025

FY21 $-5.16FY23 $-4.97FY24 $-3.35FY25 $-4.32

Total Assets

+4.8% YoY

$351.5MFY 2025

FY21 $904.2MFY23 $479.4MFY24 $335.6MFY25 $351.5M

Op. Cash Flow

-15.9% YoY

$-136.0MFY 2025

FY21 $-182.3MFY23 $-154.2MFY24 $-117.3MFY25 $-136.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Net Income	$-230.0M -30.5%	$-176.2M +32.4%	$-260.5M +2.4%	$-267.0M -100.6%	$-133.1M -181.0%	$-47.4M
Operating Income	$-234.4M -25.4%	$-186.8M +32.6%	$-277.3M -3.8%	$-267.1M -96.4%	$-136.0M -176.5%	$-49.2M
EPS (Diluted)	$-4.32 -29.0%	$-3.35 +32.6%	$-4.97 +3.7%	$-5.16 -77.3%	$-2.91	—
Total Assets	$351.5M +4.8%	$335.6M -30.0%	$479.4M -47.0%	$904.2M -15.3%	$1.07B +197.4%	$358.9M
Operating Cash Flow	$-136.0M -15.9%	$-117.3M +23.9%	$-154.2M +15.4%	$-182.3M -118.5%	$-83.4M -113.1%	$-39.1M

AI Insight: KOD Financial Trends

Equity nearly halved over eight quarters as persistent ~$55–60M quarterly cash burn accelerates, leaving Kodiak with no revenue and a shrinking capital base.

• Operating losses widened from -$48M in Q2 2024 to -$60M in Q1 2026, a roughly 25% deterioration over eight quarters.

• Operating cash outflow intensified from -$26M in Q2 2024 to -$40M in Q1 2026, signaling accelerating cash consumption.

• Equity collapsed from $215M in Q2 2024 to $24M in Q3 2025 before recovering to $157M in Q4 2025, likely reflecting a capital raise.

⚠ Equity of $112M in Q1 2026 versus ~$40M quarterly cash burn implies roughly 2–3 quarters of runway without additional financing.

⚠ Zero revenue across all eight quarters; any commercial or partnership milestone triggering revenue would be a critical positive inflection.

⚠ The Q4 2025 equity jump from $24M to $157M warrants scrutiny — dilution terms from that apparent raise could weigh on shareholders.

AI Insight: KOD Ratio Trends

Kodiak Sciences shows persistently deep losses with ROA worsening from -44.9% in Q2 2024 to -84.6% in Q2 2025 before a partial TTM recovery to -75.4%.

• ROA deteriorated from -44.9% in Q2 2024 to -84.6% in Q2 2025, reflecting accelerating asset consumption with no revenue offset.

• ROE deepened from -84.1% in Q2 2024 to -144.2% in Q4 2025, signaling continued equity erosion over six quarters.

• TTM ROA of -75.4% through Q1 2026 is slightly less negative than the Q2 2025 trough of -84.6%, a tentative stabilization.

⚠ OpMargin, NPM, ROIC, and D/E are absent across all periods — data gaps make it impossible to assess operational efficiency or leverage trajectory.

⚠ ROE hit -144.2% in Q4 2025; if equity base continues shrinking, even flat losses will push this ratio further negative.

Get alerted when KOD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kodiak Sciences Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KOD

BAKER BROS. ADVISORS LP
$759.3M19,919,186 sh
BlackRock, Inc.
$150.0M3,935,302 sh
STATE STREET CORP
$85.8M2,250,920 sh
BRAIDWELL LP
$69.3M1,818,665 sh
VANGUARD CAPITAL MANAGEMENT LLC
$65.5M1,717,076 sh
GOLDMAN SACHS GROUP INC
$64.4M1,689,003 sh
RTW INVESTMENTS, LP
$56.7M1,487,934 sh
TCG Crossover Management, LLC
$55.1M1,445,538 sh
Boxer Capital Management, LLC
$51.9M1,361,000 sh
JANUS HENDERSON GROUP PLC
$50.5M1,325,457 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$759.3M	19,919,186
BlackRock, Inc.	$150.0M	3,935,302
STATE STREET CORP	$85.8M	2,250,920
BRAIDWELL LP	$69.3M	1,818,665
VANGUARD CAPITAL MANAGEMENT LLC	$65.5M	1,717,076
GOLDMAN SACHS GROUP INC	$64.4M	1,689,003
RTW INVESTMENTS, LP	$56.7M	1,487,934
TCG Crossover Management, LLC	$55.1M	1,445,538
Boxer Capital Management, LLC	$51.9M	1,361,000
JANUS HENDERSON GROUP PLC	$50.5M	1,325,457

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KOD on your watchlist

Track score changes the day Kodiak Sciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KOD a good stock to buy?

13F Pro's AI-powered analysis of Kodiak Sciences Inc. (KOD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KOD are available on the KOD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KOD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KOD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kodiak Sciences Inc.'s investment landscape.